Targeting PIK3CA in HER2-positive breast cancer: what are the opportunities and the challenges?

Biomarkers in MedicineVol. 15, No. 9 EditorialTargeting PIK3CA in HER2-positive breast cancer: what are the opportunities and the challenges?Joseph Zouein, Charbel Noujaim & Hampig Raphael KourieJoseph Zouein https://orcid.org/0000-0003-0078-8582Hematology-Oncology Department, Faculty of Medicine, Saint Joseph University of Beirut, LebanonSearch for more papers by this author, Charbel NoujaimHematology-Oncology Department, Faculty of Medicine, Saint Joseph University of Beirut, LebanonSearch for more papers by this author & Hampig Raphael Kourie*Author for correspondence: E-mail Address: hampig.kourie@hotmail.comHematology-Oncology Department, Faculty of Medicine, Saint Joseph University of Beirut, LebanonSearch for more papers by this authorPublished Online:1 Jun 2021https://doi.org/10.2217/bmm-2021-0236AboutSectionsView ArticleView Full TextPDF/EPUB ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareShare onFacebookTwitterLinkedInReddit View articleKeywords: anti-HER2breast cancerHER2PI3K inhibitorsPIK3CAPapers of special note have been highlighted as: • of interest; •• of considerable interestReferences1. IARC Breast fact sheet. https://gco.iarc.fr/today/data/factsheets/cancers/20-Breast-fact-sheet.pdfGoogle Scholar2. Azamjah N, Soltan-Zadeh Y, Zayeri F. Global trend of breast cancer mortality rate: a 25-year study. Asian Pac. J. Cancer Prev. 20(7), 2015–2020 (2019).Crossref, Medline, Google Scholar3. Waks AG, Winer EP. Breast cancer treatment: a review. JAMA 321(3), 288–300 (2019).Crossref, Medline, CAS, Google Scholar4. Figueroa-Magalhães MC, Jelovac D, Connolly R, Wolff AC. Treatment of HER2-positive breast cancer. Breast Edinb. Scotl. 23(2), 128–136 (2014).Crossref, Medline, Google Scholar5. U.S. Food & Drug Administration. FDA approves fam-trastuzumab deruxtecan-nxki for unresectable or metastatic HER2 positive breast cancer (2019). https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-fam-trastuzumab-deruxtecan-nxki-unresectable-or-metastatic-her2-positive-breast-cancerGoogle Scholar6. U.S. Food & Drug Administration. FDA approves neratinib for metastatic HER2-positive breast cancer (2020). https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-neratinib-metastatic-her2-positive-breast-cancerGoogle Scholar7. U.S. Food & Drug Administration. FDA approves tucatinib for patients with HER2-positive metastatic breast cancer (2020). https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-tucatinib-patients-her2-positive-metastatic-breast-cancerGoogle Scholar8. U.S. Food & Drug Administration. FDA approves margetuximab for metastatic HER2-positive breast cancer (2020). https://www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-margetuximab-metastatic-her2-positive-breast-cancerGoogle Scholar9. Jensen JD, Knoop A, Laenkholm AV et al. PIK3CA mutations, PTEN, and pHER2 expression and impact on outcome in HER2-positive early-stage breast cancer patients treated with adjuvant chemotherapy and trastuzumab. Ann. Oncol. 23(8), 2034–2042 (2012). • Describes the resistance mechanisms to anti-HER2 therapies.Crossref, Medline, CAS, Google Scholar10. Pernas S, Tolaney SM. HER2-positive breast cancer: new therapeutic frontiers and overcoming resistance. Ther. Adv. Med. Oncol. 11, 1758835919833519 (2019).Crossref, Google Scholar11. Goel S, Krop IE. PIK3CA mutations in HER2-positive breast cancer: an ongoing conundrum. Ann. Oncol. 27(8), 1368–1372 (2016). • Describes the effect of the PIK3CA mutation.Crossref, Medline, CAS, Google Scholar12. Ellis H, Ma CX. PI3K inhibitors in breast cancer therapy. Curr. Oncol. Rep. 21(12), 110 (2019).Crossref, Medline, Google Scholar13. Saikia KK, Panigrahi MK, Mehta A, Kumar D. Clinico-pathological features of PIK3CA mutation in HER2-positive breast cancer of Indian population. Indian J. Surg. Oncol. 9(3), 381–386 (2018).Crossref, Medline, Google Scholar14. Seo Y, Park YH, Ahn JS et al. PIK3CA mutations and neoadjuvant therapy outcome in patients with human epidermal growth factor receptor 2-positive breast cancer: a sequential analysis. J. Breast Cancer 21(4), 382–390 (2018).Crossref, Medline, Google Scholar15. Fujimoto Y, Morita TY, Ohashi A et al. Combination treatment with a PI3K/Akt/mTOR pathway inhibitor overcomes resistance to anti-HER2 therapy in PIK3CA-mutant HER2-positive breast cancer cells. Sci. Rep. 10(1), 21762 (2020).Crossref, Medline, CAS, Google Scholar16. U.S. Food & Drug Administration. The therascreen PIK3CA RGQ PCR Kit - P190001 and P190004 (2019). https://www.fda.gov/medical-devices/recently-approved-devices/therascreen-pik3ca-rgq-pcr-kit-p190001-and-p190004Google Scholar17. U.S. Food & Drug Administration. FoundationOne®CDx - P170019/S006 (2019). https://www.fda.gov/medical-devices/recently-approved-devices/foundationonercdx-p170019s006Google Scholar18. du Rusquec P, Blonz C, Frenel JS, Campone M. Targeting the PI3K/Akt/mTOR pathway in estrogen-receptor positive HER2 negative advanced breast cancer. Ther. Adv. Med. Oncol. 12, 1758835920940939 (2020).Crossref, Google Scholar19. Mosele F, Stefanovska B, Lusque A et al. Outcome and molecular landscape of patients with PIK3CA-mutated metastatic breast cancer. Ann. Oncol. 31(3), 377–386 (2020).Crossref, Medline, CAS, Google Scholar20. Klocker EV, Suppan C. Biomarkers in HER2- positive disease. Breast Care Basel Switz. 15(6), 586–593 (2020).Crossref, Medline, Google Scholar21. Baselga J, Lewis Phillips GD, Verma S et al. Relationship between tumor biomarkers and efficacy in EMILIA, a Phase III study of trastuzumab emtansine in HER2-positive metastatic breast cancer. Clin. Cancer Res. 22(15), 3755–3763 (2016).Crossref, Medline, CAS, Google Scholar22. Nishimura R, Toh U, Tanaka M et al. Role of HER2-related biomarkers (HER2, p95HER2, HER3, PTEN, and PIK3CA) in the efficacy of lapatinib plus capecitabine in HER2-positive advanced breast cancer refractory to trastuzumab. Oncology 93(1), 51–61 (2017). • Describes the rationale behind combining phosphatidylinositol 3-kinase (PI3K) inhibitors with anti-HER2 therapies.Crossref, Medline, CAS, Google Scholar23. FDA approves first PI3K inhibitor for breast cancer (2020). https://www.fda.gov/news-events/press-announcements/fda-approves-first-pi3k-inhibitor-breast-cancerGoogle Scholar24. Oliveira M, Villagrasa P, Ciruelos E et al. Abstract OT-35-01: Solti-1507 A Phase Ib study of ipatasertib and anti-HER2 therapy in HER2-positive advanced breast cancer with PIK3CA mutation (ipather). Cancer Res. 81(Suppl. 4), OT-OT-35-01 (2021). •• Evaluates the association of pan-PI3K inhibitors with anti-HER2 drugs.Medline, Google Scholar25. Guerin M, Rezai K, Isambert N et al. PIKHER2: A Phase IB study evaluating buparlisib in combination with lapatinib in trastuzumab-resistant HER2-positive advanced breast cancer. Eur. J. Cancer 86, 28–36 (2017).Crossref, Medline, CAS, Google Scholar26. Loibl S, de la Pena L, Nekljudova V et al. Neoadjuvant buparlisib plus trastuzumab and paclitaxel for women with HER2+ primary breast cancer: a randomised, double-blind, placebo-controlled Phase II trial (NeoPHOEBE). Eur. J. Cancer 85, 133–145 (2017). •• Evaluates the association of alpha PI3K inhibitors with anti-HER2 drugs.Crossref, Medline, CAS, Google Scholar27. Jain S, Shah AN, Santa-Maria CA et al. Phase I study of alpelisib (BYL-719) and trastuzumab emtansine (T-DM1) in HER2-positive metastatic breast cancer (MBC) after trastuzumab and taxane therapy. Breast Cancer Res. Treat. 171(2), 371–381 (2018).Crossref, Medline, CAS, Google Scholar28. Jain S, Santa-Maria CA, Rademaker A, Giles FJ, Cristofanilli M, Gradishar WJ. Phase I study of alpelisib (BYL-719) and T-DM1 in HER2-positive metastatic breast cancer after trastuzumab and taxane therapy. J. Clin. Oncol. 35(Suppl. 15), 1026 (2017).Crossref, Google Scholar29. Shah PD, Chandarlapaty S, Ulaner G et al. Abstract OT3-1-05: Phase I, open-label study evaluating the safety and tolerability of LJM716, BYL719 and trastuzumab in patients with metastatic HER2+ breast cancer. Cancer Res. 75(Suppl. 9), OT3-OT3-1–05 (2015).Google Scholar30. Shah PD, Chandarlapaty S, Dickler MN et al. Phase I study of LJM716, BYL719, and trastuzumab in patients (pts) with HER2-amplified (HER2+) metastatic breast cancer (MBC). J. Clin. Oncol. 33(Suppl. 15), 590 (2015).Crossref, Google Scholar31. Hurvitz SA, Chia SKL, Ciruelos EM et al. EPIK-B2: a Phase III study of alpelisib (ALP) as maintenance therapy with trastuzumab (T) and pertuzumab (P) in patients (pts) with PIK3CA-mutated (mut) human epidermal growth factor receptor-2–positive (HER2+) advanced breast cancer (ABC). Ann. Oncol. 31(Suppl. 4), S389–S390 (2020).Crossref, Google Scholar32. Piccart-Gebhart MJ, Aftimos PG, Duhoux FP et al. B-PRECISE-01 study: a Phase Ib trial of MEN1611, a PI3K inhibitor, combined with trastuzumab ± fulvestrant for the treatment of HER2-positive advanced or metastatic breast cancer. J. Clin. Oncol. 37(Suppl. 15), TPS1101 (2019).Crossref, Google Scholar33. Keegan NM, Furney S, Walshe J et al. Abstract P1-19-24: A Phase Ib trial of copanlisib in combination with trastuzumab in pretreated recurrent or metastatic HER2-positive breast cancer “PantHER”. Cancer Res. 80(Suppl. 4), P1-P1-19–24 (2020).Google Scholar34. Metzger Filho O, Goel S, Barry WT et al. A mouse–human Phase I co-clinical trial of taselisib in combination with TDM1 in advanced HER2-positive breast cancer (MBC). J. Clin. Oncol. 35(Suppl. 15), 1030 (2017).Crossref, Google ScholarFiguresReferencesRelatedDetailsCited BySNORD60 promotes the tumorigenesis and progression of endometrial cancer through binding PIK3CA and regulating PI3K/AKT/mTOR signaling pathway23 December 2022 | Molecular Carcinogenesis, Vol. 15A Potential PIK3CA Inhibitor to Develop an Anticancer Drug18 July 2022 | ChemistrySelect, Vol. 7, No. 27 Vol. 15, No. 9 Follow us on social media for the latest updates Metrics Downloaded 282 times History Received 22 March 2021 Accepted 24 March 2021 Published online 1 June 2021 Published in print June 2021 Information© 2021 Future Medicine LtdKeywordsanti-HER2breast cancerHER2PI3K inhibitorsPIK3CAAuthor contributionsHR Kourie contributed in conception of the study; J Zouein contributed in reviewing of the literature; J Zouein, HR Kourie did drafting of the manuscript; HR Kourie and C Noujaim contributed in reviewing of the manuscript.Financial & competing interests disclosureThe authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.No writing assistance was utilized in the production of this manuscript.PDF download